Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
CAS Registry Number
81098-60-4
Molecular formula
C23H29ClFN3O4
Molecular weight
465.95 g/mol
Drug class
Serotonin 5-HT4 receptor agonistgastrointestinal prokinetic agent (withdrawn or restricted in many jurisdictions)
Mechanism of action
Stimulates 5-HT4 receptors on enteric neurons, enhancing acetylcholine release and increasing gastrointestinal motility. Cisapride can prolong cardiac repolarisation through hERG potassium-channel inhibition, creating risk of QT prolongation and serious arrhythmias.
Indications / reported uses
Historical use for severe gastro-oesophageal reflux and delayed gastric emptying; withdrawn or restricted in many jurisdictions due to QT prolongation and potentially fatal ventricular arrhythmias. It should not be represented as a routine currently available treatment.
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Cisapride Environmental Risk Assessment (ERA) (the Cisapride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.